Canadian Cancer Survivor Network Prostate Patient Questionnaire - Zytiga ZYTIGA SURVEYThe purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing advanced stages of prostate cancer from patients and caregivers in order to complete a patient evidence submission for a new medication for metastatic castration-resistant prostate cancer called Zytiga (abiraterone acetate). This medication has been available in Canada since 2011 for patients with metastatic castration-resistant prostate cancer in the post-chemotherapy stages. This national cancer drug review will consider its use in the pre-chemotherapy stage. The pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.The survey will be available starting now and remain open until April 5, 2013.Thank you for your participation. Question Title * 1. What are the symptoms or problems you experience with advanced prostate cancer that affect your day-to-day living and quality of life? Fatigue Sexual dysfunction Not sleeping at night - restless Weight loss – lack of appetite Pain Fractures or fear of fracture Urinary incontinence Living with uncertainty Feeling isolated or lonely Anxiety, panic attacks or depression Other (please specify) Question Title * 2. Which of these symptoms are the most important to control. Please pick your top 5: Fatigue Sexual dysfunction Not sleeping at night - restless Weight loss – lack of appetite Pain Fractures or fear of fracture Urinary incontinence Living with uncertainty Feeling isolated or lonely Anxiety, panic attacks or depression Other (please specify) Question Title * 3. What therapies or treatments are you currently using or did you use to treat your disease? Please check all that apply. No treatment ("watch and wait") Docetaxel (Taxotere) Abiraterone acetate (Zytiga) Enzalutamide (Xtandi) Radiation therapy Steriods Other hormone therapy Clinical trial Other (please specify) Question Title * 4. How effective have the therapies or treatments listed in question 3 been at controlling common aspects of advanced prostate cancer? Please check all that apply. Very effective Somewhat effective Not very effective Not effective at all No treatment ("watch and wait") No treatment ("watch and wait") Very effective No treatment ("watch and wait") Somewhat effective No treatment ("watch and wait") Not very effective No treatment ("watch and wait") Not effective at all Docetaxel (Taxotere) Docetaxel (Taxotere) Very effective Docetaxel (Taxotere) Somewhat effective Docetaxel (Taxotere) Not very effective Docetaxel (Taxotere) Not effective at all Abiraterone acetate (Zytiga) Abiraterone acetate (Zytiga) Very effective Abiraterone acetate (Zytiga) Somewhat effective Abiraterone acetate (Zytiga) Not very effective Abiraterone acetate (Zytiga) Not effective at all Enzalutamide (Xtandi) Enzalutamide (Xtandi) Very effective Enzalutamide (Xtandi) Somewhat effective Enzalutamide (Xtandi) Not very effective Enzalutamide (Xtandi) Not effective at all Radiation therapy Radiation therapy Very effective Radiation therapy Somewhat effective Radiation therapy Not very effective Radiation therapy Not effective at all Steriods Steriods Very effective Steriods Somewhat effective Steriods Not very effective Steriods Not effective at all Other hormone therapy Other hormone therapy Very effective Other hormone therapy Somewhat effective Other hormone therapy Not very effective Other hormone therapy Not effective at all Clinical trial Clinical trial Very effective Clinical trial Somewhat effective Clinical trial Not very effective Clinical trial Not effective at all Other (please specify) Question Title * 5. What are the common adverse effects you have experienced? Anemia Diarrhea Nausea and vomiting Risk of infection N/A (Not on therapy at this stage) Other (please describe below) Other adverse effects Question Title * 6. Are some adverse effects you have experienced more difficult to manage than others? Anemia Diarrhea Nausea and vomiting Risk of infection N/A (Not on therapy at this stage) Other (please describe below) Other (please specify) Question Title * 7. Have you had issues accessing current therapy? Yes Limited availability in my community Financial hardship due to cost Travel costs associated with getting therapy/treatment Supplies or issues with administration No N/A (not on therapy at this stage) Other (please specify) Question Title * 8. Are there any needs in your current therapy that are not yet being met? No N/A (Not on therapy at this stage) Yes (please describe below) Description Question Title * 9. EXPECTIONS OF A NEW DRUGNO EXPERIENCE WITH ZYTIGA (ABIRATERONE ACETATE)Please complete these questions if you have not been treated with Zytiga (abiraterone acetate)Based on the needs in question 8, how much of an improvement would be needed from the new drug to make it better than current treatment? Please describe: Next